Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke

NCT00840671 is registered in ClinicalTrials.gov with Ever Neuro Pharma GmbH as lead sponsor.

NCT NCT00840671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00840671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke
Lead sponsor
Ever Neuro Pharma GmbH
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2005
Completion date
July 31, 2008
Enrollment
119 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

stroke